VERONA PHARMA P/S (NASDAQ:VRNA) has received an average recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $34.80.
A number of equities research analysts recently weighed in on VRNA shares. Zacks Investment Research raised shares of VERONA PHARMA P/S from a “hold” rating to a “strong-buy” rating and set a $19.00 price target for the company in a research note on Saturday, May 12th. ValuEngine raised shares of VERONA PHARMA P/S from a “hold” rating to a “buy” rating in a research note on Monday, June 11th. Wedbush set a $56.00 price target on shares of VERONA PHARMA P/S and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $26.00 price target on shares of VERONA PHARMA P/S in a research note on Friday, August 10th.
Shares of NASDAQ VRNA traded down $0.35 during trading on Friday, reaching $12.95. The company had a trading volume of 1,310 shares, compared to its average volume of 2,793. VERONA PHARMA P/S has a 52 week low of $10.44 and a 52 week high of $25.55. The company has a market cap of $174.59 million, a PE ratio of -5.37 and a beta of -2.86.
VERONA PHARMA P/S (NASDAQ:VRNA) last announced its earnings results on Tuesday, August 7th. The company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.14) by $1.20. research analysts expect that VERONA PHARMA P/S will post -2.32 earnings per share for the current year.
A hedge fund recently raised its stake in VERONA PHARMA P/S stock. Foresite Capital Management III LLC increased its holdings in shares of VERONA PHARMA P/S (NASDAQ:VRNA) by 7.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 565,292 shares of the company’s stock after buying an additional 36,870 shares during the period. VERONA PHARMA P/S accounts for about 2.5% of Foresite Capital Management III LLC’s investment portfolio, making the stock its 12th biggest holding. Foresite Capital Management III LLC owned approximately 4.31% of VERONA PHARMA P/S worth $11,306,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 49.47% of the company’s stock.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
Featured Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.